Show simple item record

dc.contributor.authorSchroeder, BA
dc.contributor.authorLaFranzo, NA
dc.contributor.authorLaFleur, BJ
dc.contributor.authorGittelman, RM
dc.contributor.authorVignali, M
dc.contributor.authorZhang, S
dc.contributor.authorFlanagan, KC
dc.contributor.authorRytlewski, J
dc.contributor.authorRiolobos, L
dc.contributor.authorSchulte, BC
dc.contributor.authorKim, TS
dc.contributor.authorChen, E
dc.contributor.authorSmythe, KS
dc.contributor.authorWagner, MJ
dc.contributor.authorMantilla, JG
dc.contributor.authorCampbell, JS
dc.contributor.authorPierce, RH
dc.contributor.authorJones, RL
dc.contributor.authorCranmer, LD
dc.contributor.authorPollack, SM
dc.coverage.spatialEngland
dc.date.accessioned2022-09-13T09:55:30Z
dc.date.available2022-09-13T09:55:30Z
dc.date.issued2021-08-01
dc.identifierARTN e002812
dc.identifierjitc-2021-002812
dc.identifier.citationJournal for ImmunoTherapy of Cancer, 2021, 9 (8), pp. e002812 -
dc.identifier.issn2051-1426
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5452
dc.identifier.eissn2051-1426
dc.identifier.eissn2051-1426
dc.identifier.doi10.1136/jitc-2021-002812
dc.description.abstractBACKGROUND: Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to PD-1 inhibitors, little is known about the immune microenvironment in relation to patient prognosis. METHODS: We performed a retrospective study of 61 patients with DDLPS. We completed deep sequencing of the T-cell receptor (TCR) β-chain and RNA sequencing for predictive modeling, evaluating both immune markers and tumor escape genes. Hierarchical clustering and recursive partitioning were employed to elucidate relationships of cellular infiltrates within the tumor microenvironment, while an immune score for single markers was created as a predictive tool. RESULTS: Although many DDLPS samples had low TCR clonality, high TCR clonality combined with low T-cell fraction predicted lower 3-year overall survival (p=0.05). Higher levels of CD14+ monocytes (p=0.02) inversely correlated with 3-year recurrence-free survival (RFS), while CD4+ T-cell infiltration (p=0.05) was associated with a higher RFS. Genes associated with longer RFS included PD-1 (p=0.003), ICOS (p=0.006), BTLA (p=0.033), and CTLA4 (p=0.02). In a composite immune score, CD4+ T cells had the strongest positive predictive value, while CD14+ monocytes and M2 macrophages had the strongest negative predictive values. CONCLUSIONS: Immune cell infiltration predicts clinical outcome in DDLPS, with CD4+ cells associated with better outcomes; CD14+ cells and M2 macrophages are associated with worse outcomes. Future checkpoint inhibitor studies in DDLPS should incorporate immunosequencing and gene expression profiling techniques that can generate immune landscape profiles.
dc.formatPrint
dc.format.extente002812 -
dc.languageeng
dc.language.isoeng
dc.publisherBMJ PUBLISHING GROUP
dc.relation.ispartofJournal for ImmunoTherapy of Cancer
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectCD4-positive T-lymphocytes
dc.subjectimmunity
dc.subjectmacrophages
dc.subjectsarcoma
dc.subjecttumor microenvironment
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectCD4-Positive T-Lymphocytes
dc.subjectCell Differentiation
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectFemale
dc.subjectHumans
dc.subjectInfant
dc.subjectInfant, Newborn
dc.subjectLiposarcoma
dc.subjectMacrophages
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPatient Outcome Assessment
dc.subjectRetrospective Studies
dc.subjectYoung Adult
dc.titleCD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.
dc.typeJournal Article
dcterms.dateAccepted2021-07-26
dc.date.updated2022-09-13T09:53:46Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1136/jitc-2021-002812
rioxxterms.licenseref.startdate2021-08-01
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34465597
pubs.issue8
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1136/jitc-2021-002812
pubs.volume9
dc.contributor.icrauthorJones, Robin
icr.provenanceDeposited by Mr Arek Surman on 2022-09-13. Deposit type is initial. No. of files: 1. Files: CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. .pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0/